Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
July 16, 2018
Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018
PITTSBURGH, July 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological ...
July 16, 2018
Aeglea BioTherapeutics Appoints Dr. Bryan Lawlis to Board of Directors
AUSTIN, Texas, July 16, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for ...
July 16, 2018
AIT Therapeutics Announces Human and In-Vitro Nitric Oxide (NO) Data Presented at the 3rd Annual World Bronchiectasis Conference
GARDEN CITY, N.Y., and REHOVOT, Israel, July 16, 2018 (GLOBE NEWSWIRE) --  AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
July 12, 2018
New Preclinical Results on Onxeo’s AsiDNA™, First-in-Class DNA Repair Inhibitor, Point to Strong Synergy and Reversion of Tumor Resistance when combined to PARP inhibitors
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in ...
July 12, 2018
Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., July 12, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
July 12, 2018
Catalyst Biosciences Announces Multiple Presentations at the Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis
SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address ...
July 12, 2018
Altimmune Restructures Financing Agreement with Majority of the Remaining Series B Investors
GAITHERSBURG, Md., July 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT), a clinical-stage immunotherapeutics company focused on preventing infectious diseases, today announced it has entered ...
July 12, 2018
Pfenex Receives Milestone From Merck Associated With Clinical Advancement of Investigational 15-valent Pneumococcal Vaccine PCV-15 (V114)
SAN DIEGO, July 12, 2018 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE AMERICAN:PFNX) today announced the receipt of a milestone payment from Merck associated with the ...
July 11, 2018
AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City
ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that Chief Executive Officer Michael D. West, Ph.D., who also ...
July 11, 2018
Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements
CRANBURY, N.J., July 11, 2018 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (ONS) today announced that, on July 10, 2018, the Company received formal notice from The ...
July 2, 2018
Kuros Biosciences Reports First U.S. & UK sales of MagnetOs
SCHLIEREN (ZURICH), Switzerland, July 02, 2018 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX:KURN) announced today it recorded the first commercial use last week of MagnetOs in ...
July 2, 2018
OSE Immunotherapeutics Receives IDMC Approval to Continue “Atalante 1” Phase 3 NSCLC Clinical Trial of Tedopi®
NANTES, France, July 02, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) received approval from the Independent Data Monitoring Committee (IDMC) to continue Atalante 1, the ...
July 2, 2018
Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors
BUFFALO, N.Y., July 02, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
July 2, 2018
RedHill Biopharma Announces Allowance of Two New RHB-104 Patents Ahead of Top-Line Phase III Results for Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C., July 02, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical ...
July 2, 2018
Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis
SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor ...
July 2, 2018
BrainStorm Announces Second U.S. Manufacturing Site for NurOwn® Production
NEW YORK, PETACH TIKVA, Israel and BOSTON, July 2, 2018 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies ...
July 2, 2018
Zogenix Welcomes New Global Chief Commercial Officer
EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
July 2, 2018
PolarityTE Adds Peter Cohen, Former Board Member of the NYSE and Chairman and CEO of Cowen Inc., to the Board of Directors
SALT LAKE CITY, July 02, 2018 (GLOBE NEWSWIRE) -- PolarityTE, Inc. (COOL) today announced that Peter Cohen will join PolarityTE’s Board of Directors. Mr. Cohen ...
July 2, 2018
Fortress Biotech Announces Cyprium Therapeutics’ CUTX-101 (Copper Histidinate) Granted FDA Fast Track Designation for Treatment of Classic Menkes Disease
NEW YORK, July 02, 2018 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (FBIO) (“Fortress”), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and ...
June 29, 2018
Gemcabene Meets Primary Endpoint in INDIGO-1 Study of Severe Hypertriglyceridemia (SHTG) Patients
LIVONIA, Mich., June 28, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
Page 49 of 138